Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study-Reference-Cited by-同舟云学术

Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study

Published:2021-07 Issue:7 Volume:9 Page:427-435
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Spiekerkoetter Ute,Couce Maria L,Das Anibh M,de Laet Corinne,Dionisi-Vici Carlo,Lund Allan M,Schiff Manuel,Spada Marco,Sparve Erik,Szamosi Johan,Vara Roshni,Rudebeck Mattias

Funder

Vitaflo

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference30 articles.

1. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment;van Spronsen;Hepatology,1994

2. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec;Larochelle;Mol Genet Metab,2012

3. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase;Lindstedt;Lancet,1992

4. Long-term outcomes and practical considerations in the pharmacological management of tyrosinemia type 1;van Ginkel;Paediatr Drugs,2019

5. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice;Mayorandan;Orphanet J Rare Dis,2014

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modified by the Innovative Drugs and Strategies—Pattern of Selected Indications for Pediatric Liver Transplantation;Pediatric Transplantation;2024-07-13

2. Editorial: Corticosteroids for severe checkpoint inhibitor‐induced liver injury—Not one size fits all?;Alimentary Pharmacology & Therapeutics;2024-03-10

3. UK guideline on the transition and management of childhood liver diseases in adulthood;Alimentary Pharmacology & Therapeutics;2024-02-22

4. 3D Printing of Dietary Products for the Management of Inborn Errors of Intermediary Metabolism in Pediatric Populations;Nutrients;2023-12-25

5. Prime editing: current advances and therapeutic opportunities in human diseases;Science Bulletin;2023-12